Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study of TPN-101 in Patients With Aicardi-Goutières Syndrome (AGS)

NCT05613868 is registered in ClinicalTrials.gov with Transposon Therapeutics, Inc. as lead sponsor.

NCT NCT05613868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05613868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study of TPN-101 in Patients With Aicardi-Goutières Syndrome (AGS)
Lead sponsor
Transposon Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
March 15, 2023
Completion date
February 27, 2025
Enrollment
4 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

aicardi-goutières syndrome (ags)